【摘要】 目的探讨B7共刺激分子在人类多发性骨髓瘤细胞上的表达及沙利度胺对其表达的调节作用。方法通过细胞培养研究沙利度胺对人骨髓瘤细胞系B7.1分子表达的调节作用,用流式细胞仪检测B7分子的表达。结果人类多发性骨髓瘤细胞系及患者骨髓瘤细胞缺乏B7.1分子的表达,阳性细胞百分比分别为0.8及2.19±2.13,B7.2分子的表达分别为26.4及30.28±28.11。与阴性对照组相比,除0.1μg/ml组外,随着沙利度胺浓度的增加,CD80分子表达的阳性细胞百分比明显提高(P<0.01),5μg/ml浓度组为(17.7±1.53)%,达到最高。结论多发性骨髓瘤细胞不表达或低表达B7.1分子,上调B7.1分子的表达可能是沙利度胺治疗多发性骨髓瘤有效的机制之一。更多还原

【Abstract】 Objective To investigate the expression of B7 co-stimulatory molecules in human multiple myeloma (MM) and the immunoregulatory effects of thalidomide on B7.1 co-stimulator. Methods The immunoregulatory effects of thalidomide on the expression of B7-1 in human MM cell line was examined by detecting the changes in the expression of B7 co-stimulator on the cells using flow cytometry following the drug treatment. Results The expression of B7.1 co-stimulator was lowly expressed in human MM cell line and MM patients, with a positivity rate of 0.8 and (2.19±2.13) for B7.1 and a rate of 26.4 and (30.28±28.11) for B7.2, respectively. Compared with the control group, the thalidomide-treated cells showed significantly increased percentage of CD-80 positive cells in a dose-dependent manner (but not at 0.1 μg/ml) (P<0.01), with the highest percentage reaching (17.7±1.53)% at thalidomide concentration of 5 μg/ml. Conclusion MM cells express low or undetectable levels of B7.1. Thalidomide can up-regulate the expression of B7-1 molecules on myeloma cells, which is probably one of the therapeutic mechanisms of thalidomide .更多还原